| metastatic/advanced - esophageal cancer (mEC) | |||
| mEC - (neo)adjuvant (NA) | mEC - 1st line (L1) | mEC - 2nd line (L2) | |
| anti-PD-(L)1 | |||
| camrelizumab based treatment | |||
| camrelizumab alone | ESCORT | ||
| nivolumab based treatment | |||
| nivolumab alone | CheckMate 577 | ATTRACTION-3 | |
| pembrolizumab based treatment | |||
| pembrolizumab alone | KEYNOTE-181 | ||
| pembrolizumab plus SoC | KEYNOTE-590 | ||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
